BFM
INSY

Boothbay Fund Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Boothbay Fund Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-61,600
Closed -$621K – 1022
2018
Q3 		$621K Buy
+61,600
New +$491K 0.06% 303

Other funds holding INSY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Boothbay Fund Management's INSY Position: Q4 2018 in Review

Boothbay Fund Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2018, closing a stake of 61,600 shares — an estimated $621K sold.

Boothbay Fund Management first reported a position in INSY in Q3 2018 and held it in 1 quarter. The position peaked at $621K in Q3 2018. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2018.

  • Boothbay Fund Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Boothbay Fund Management sold 61,600 Insys Therapeutics, Inc. shares in Q4 2018, an estimated $621K.
  • Boothbay Fund Management first reported a position in Insys Therapeutics, Inc. in Q3 2018 and held it in 1 quarter.
  • Boothbay Fund Management's Insys Therapeutics, Inc. position peaked at $621K in Q3 2018.
  • 113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2018.

Based on Boothbay Fund Management's 13F filing for Q4 2018, filed 14 Feb 2019.